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O B J E C T I V E S The aim of this study was to evaluate the impact of renal function by estimated
glomerular ﬁltration rate (eGFR) on risk stratiﬁcation of diabetic and nondiabetic patients undergoing
myocardial perfusion imaging (MPI) by single-photon emission computed tomography for suspected
ischemia.
B A C KG ROUND Coronary artery disease is the leading cause of death among diabetic persons;
however, diabetic persons are a very heterogeneous group in terms of cardiovascular risk, necessitating
further risk stratiﬁcation.
METHOD S Patients (n 1,747, age 65 10 years, 37% diabetic) undergoing MPI were followed for
cardiac death (CD) for a mean of 2.15  0.8 years. Chronic kidney disease (CKD) was deﬁned by an eGFR
60 ml/min.
R E S U L T S In the presence of a normal scan, annual CD rate was 0.9% for those with no diabetes mellitus
(DM) and no CKD, 0.5% in the DM alone group, 2.35% in CKD alone, and 2.9% in those with both DM and
CKD (p 0.001). Patients with DMCKD had a 2.7-fold risk of CD compared with no DM no CKD (p 0.001)
after controlling for age, ejection fraction, history of coronary artery disease, and other risk factors. The risk
of CD increased as a function of the presence and severity of perfusion defects, regardless of CKD or DM
status. Presence of CKD conferred a several-fold higher risk of CD for the various strata of perfusion defects.
Log-rank test for difference in probability of CD was nonsigniﬁcant for comparison between patients with no
DM no CKD and those with DM alone (p  0.73) but was signiﬁcant for comparison between patients with
no DM no CKD and patients with CKD alone (p  0.001) or DMCKD (p  0.001).
CONC L U S I O N S MPI and eGFR provide valuable risk stratiﬁcation for diabetic and nondiabetic
patients. Diabetic patients without CKD seem to have similar short-term cardiac outcomes compared with
nondiabetic patients. Underlying CKD seems to identify a high-risk subgroup of diabetic patients. (J Am Coll
Cardiol Img 2010;3:734–45) © 2010 by the American College of Cardiology Foundation
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735he prevalence of diabetes mellitus (DM) con-
tinues to grow at an alarming rate. Recent
figures estimate that 17.5 million people in the
U.S. have diabetes, and with an aging popula-
ion and an obesity epidemic, these figures are pre-
icted to rise (1). The complications from diabetes are
aried and involve multiple organ systems. However,
5% to 70% of diabetic mortality is principally caused
See page 746
y cardiovascular disease (2). Given this high bur-
en of cardiovascular mortality, the National Cho-
esterol Education Program elevated type 2 diabetes
o the highest risk category by making it a coronary
eart disease risk-equivalent (3). However, diabetic
ersons are a heterogeneous group, and there are
ubgroups of diabetic persons at lower risk for
ardiovascular complications and subgroups at high
isk, in need of intensive risk factor modification,
creening, treatment, and close clinical follow-up.
The impact of chronic kidney disease (CKD) on
ardiovascular and all-cause mortality (ACM) has
een well-established (4–9). In the most recent
ractice guidelines from the National Kidney Foun-
ation and the Joint National Committee on Pre-
ention, Detection, Evaluation, and Treatment of
igh Blood Pressure; it was recommended that
ndividuals with CKD be considered in the highest
isk group for cardiovascular disease (10,11).
With the strong links among CKD, diabetes, and
ardiovascular mortality and the prevalence reach-
ng epidemic proportions, the need for effective risk
tratification of diabetic persons assumes unprece-
ented significance. Multiple studies have tried to
ddress the issue of cardiac risk stratification of
iabetic patients by noninvasive testing. In the
ecently published outcomes of the DIAD (Detec-
ion of Ischemia in Asymptomatic Diabetics) study,
he event rate overall at 5 years was very low, and
creening with myocardial perfusion imaging
MPI) by single-photon emission computed to-
ography did not seem to affect the risk profile. On
he basis of these results, the authors concluded that
outine screening in asymptomatic diabetic patients
annot be justified (12). To further investigate the
ssue of effective risk stratification, we examined the
mpact of renal function as measured by estimated
lomerular filtration rate (eGFR) on risk stratifying
iabetic and nondiabetic patients undergoing stress
PI for evaluation of suspected coronary arteryisease (CAD). iE T H O D S
opulation. This was an observational retrospective
ohort of 1,747 consecutive patients with known or
uspected CAD undergoing stress MPI between
une 2002 and July 2005 at the William S. Middle-
on Memorial Veterans Hospital (VA), Madison,
isconsin. The study was approved by the VA
nstitutional review board.
ources of data. With the VISTA (Veterans Affairs
nformation System Technology and Architecture)
atabase, we reviewed inpatient and outpatient
lectronic records for patients. The VA, America’s
argest integrated health care system, has a
niform, fully electronic national record
ystem called the CPRS (Computerized
atient Record System). It provides net-
orked, robust, and timely retrieval of
emote-site patient data. All clinic, emer-
ency department visits, and hospital stay
ecords including outpatient phone con-
acts are electronically stored in CPRS.
ospital stays outside the VA are either
ecorded in VA physician notes or scanned
nd stored electronically in the VA sys-
em. Manual extraction of patient infor-
ation and records from the VISTA/
PRS interface program was performed
y 3 investigators who were blinded to the
enal and single-photon emission com-
uted tomography (SPECT) data.
The initial patient visit (closest to the
ime of MPI) was used to determine demo-
raphic data, height, weight, cardiovascular
ymptoms, baseline electrocardiogram
ECG), and baseline cardiac risk factors.
he presence of risk factors was determined
y diagnosis documented by a physician,
upportive laboratory data, or medications
hat would support these diagnoses. The
resence of diabetes required physician doc-
mentation or the presence of diabetic medications
ncluding insulin and oral hypoglycemic agents. The
resence of CAD required either a previous coronary
vent or a documented CAD diagnosis via cardiac
tress testing or coronary angiography. Additional
ata including medications at the time of MPI and
aboratory findings, specifically hemoglobin and cre-
tinine levels, were obtained from CPRS. Laboratory
ata was obtained within a mean of 49  20 days
rom the time of MPI evaluation.
maging and stress protocol. Rest-stress MPI imag-
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736as performed. A symptom-limited treadmill exer-
ise test was initiated in 32% of patients with
tandard protocols with a 12-lead ECG recording
ach minute of exercise. At near-maximal exercise
85% age predicted heart rate), a 20- to 30-mCi
ose of technetium-99 or tetrofosmin was injected
actual patient dose varied with patient weight), and
xercise continued for 1 min after injection. Image
cquisition was initiated 15 min after isotope injec-
ion. Whenever possible, beta-blockers, calcium
hannel blockers, and caffeine products were dis-
ontinued 24 h before testing, and nitrate com-
ounds were discontinued 6 h before testing.
If the patient was predetermined to be unable to
ndergo a treadmill protocol or unable to achieve
5% of maximal predicted heart rate, the test was
erformed pharmacologically with use of a 4-min
denosine infusion protocol (68% of the study
roup). Institutional protocol allowed for use of
nly adenosine for pharmacological MPI studies.
atients who were unable to exercise and had
ontraindications to adenosine (e.g., severe chronic
bstructive pulmonary disease) generally underwent
obutamine stress echocardiography or cardiac
atheterization. Technetium-99m was injected at
he end of the third minute of infusion, and
PECT was initiated approximately 60 min after
he end of the adenosine infusion (12). During both
ypes of stress tests, blood pressure was measured
nd recorded at rest, at the end of each stress stage,
nd at peak stress. Maximal degree of ST-segment
hange at 80 ms after the J point of the ECG was
easured and assessed as horizontal, up-sloping, or
own-sloping.
PECT acquisition protocol. The SPECT studies
ere performed with dual head cardio epic cam-
ra with a circular 180° acquisition for 64 projec-
ions at 20 to 25 s/projection (13). During
maging, a 10% window centered on the 140-keV
eak was used for technetium-99m tracers. The
ow-pass Butterworth filter was used for all
PECT studies. Gated scan could not be per-
ormed in 5% of the patients because of arrhyth-
ias, primarily atrial fibrillation.
maging interpretation and scintigraphic indexes.
emiquantitative visual interpretation was per-
ormed with short-axis and vertical long-axis, and
yocardial tomograms were divided into 20 seg-
ents for each study, as previously described (14).
summed stress score (SSS) was obtained by
dding the scores of the 20 segments of the stress
estamibi images with the QP/QS software (15,16).
ach segment was scored with a 5-point scoring zystem (0: normal, 1: mildly reduced, 2: moderately
educed, 3: severely reduced, 4: absent uptake)
14,16). The sum of segment scores at stress (SSS),
cores at rest (summed rest score [SRS]), and
ifferences between stress and rest score (summed
ifference score [SDS]) were calculated (14–18).
atients were divided into groups on the basis of
heir SSS. Summed stress scores 4 were consid-
red normal, 4 to 8 were considered mildly abnor-
al, and8 were considered moderately to severely
bnormal (15,16,18). Patients were also divided
nto groups on the basis of their SDS and SRS into
ormal (2), mildly abnormal (2 to 6), and mod-
rate to severely abnormal (6) (17). High-risk
can was defined as moderate to severely abnormal
PI and/or left ventricular ejection fraction
LVEF) 40%. Presence of ischemia and scar was
etermined by the severity of SDS and SRS, re-
pectively. Post-stress LVEF obtained in 95% of
atients by gated SPECT was also assessed with
P/QS software. The studies were interpreted by 3
oard certified nuclear cardiologists who were
linded to the demographic and laboratory data but
ot to sex.
lassiﬁcation of renal dysfunction. Estimated glomer-
lar filtration rate was calculated with the 4-variable
odified diet in renal disease “MDRD” equation:
FR (ml/min/1.73 m2)  175  (Scr)
1.154 
Age)0.203  0.742 (if female)  1.210 (if African
merican) (19,20). The CKD was defined with the
ational Kidney foundation definition of an eGFR
60 ml/min/1.73 m2 (21) and was present in 632
atients (36%). Serum creatinine used to calculate
GFR was obtained within 49  20 days from the
ime of MPI. Thirty-two patients in acute renal
ailure (defined by an increase in serum creatinine of
0.5 mg/dl in 2 weeks or an increase of 20%
ver baseline if baseline serum creatinine was 2.5
g/dl) were excluded.
atient follow-up and end points. Patients were fol-
owed for a mean duration of 2.15  0.8 years.
he minimum duration of follow-up was 6
onths (for those who had no events, shorter for
hose who died) with only 44 patients that had
ollow-up of 1 year. The primary end point was
ardiac death (CD) defined as death from any
ardiac cause including fatal myocardial infarc-
ion, sudden arrhythmic death, and decompen-
ated heart failure; secondary end points were
CM and a composite of CD and nonfatal
yocardial infarction (NFMI) (defined by the
ppropriate combination of elevated cardiac en-
ymes, electrocardiographic changes, and isch-
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737mic symptoms). Mortality data was gathered
rom the VA patient records and confirmed by
he Social Security Death Index. Death status
as determined as of month/year. Cause of death
as adjudicated by 3 independent reviewers
blinded to the MPI and demographic data)
hrough patient chart review including death
ertificate and physician’s records. Conflicts were
esolved by global consensus or by the senior
nvestigator.
In clinical settings, patients with moderate or
evere stress-induced ischemia are usually treated by
oronary revascularization after the SPECT study.
his sort of selection bias cannot be avoided in a
ohort study. However, the estimation of event
isks before revascularization on the basis of the
rognostic database is meaningful for patient man-
gement. To address the issue of the impact of
evascularization on outcomes, a separate analysis
as carried out excluding patients with early revas-
ularization defined as 60 days after the index
erfusion study.
tatistical analysis. For analysis of baseline charac-
eristics, all subjects were classified on the basis of
he presence or absence of DM and then further
tratified by the presence or absence of CKD
eGFR above or below 60 ml/min/1.73 m2). Pa-
Table 1. Baseline Characteristics
Characteristic
Nondiabetic (n  1,107)
eGFR >60 ml/min
(n  759)
eGFR <60 ml/min
(n  348)
Age (yrs) 62 10 70 10
Men 98% (744) 95% (334)
Revascularization 32% (241) 35% (122)
Smoking history 31% (233) 23% (80)
Hypertension 69% (526) 75% (262)
Known CAD 40% (307) 45% (158)
History of MI 19% (142) 21% (72)
Hyperlipidemia 73% (544) 65% (226)
Angina 35% (267) 25% (87)
SOB 15% (112) 14% (48)
Mean eGFR 78 14 46 12
BMI 30 kg/m2 43% (328) 41% (143)
Pharm stress 60% (454) 76% (265)
Beta blockers 59% (425) 63% (208)
ACE inhibitors 50% (362) 54% (178)
CCB 16% (117) 32% (106)
Statin 64% (465) 69% (227)
LVEF 57 12 51 14
LVEF 40% 11% (83) 19% (66)
ACE  angiotensin-converting enzyme; BMI  body mass index; CAD  coron
ﬁltration rate; LVEF  left ventricular ejection fraction; MI  myocardial infarction;ients were hence classified into 4 groups on the
asis of presence or absence of DM and CKD:
) No DM No CKD; 2) DM only (no CKD);
) CKD only (no DM); and 4) DMCKD.
Student t tests or Wilcoxon rank sum tests (for
kewed data) were used to compare subject charac-
eristics across renal function levels within each
iabetes status. Chi-square tests were used for
omparing dichotomous or categorical variables.
Unadjusted annual event rates for those with and
ithout scan defects on the basis of diabetes and
KD status were expressed as cases/100 person-
ears. Person-years were based on length of follow-
p, calculated as the number of years from the
xamination to the CD event or censoring. Event
ates on the basis of presence of ischemia and scar in
ach of the 4 groups were calculated in a similar
anner. Furthermore, median SSS, SDS, and
GFR were calculated for patients with and without
ach of these outcomes and compared with Wil-
oxon rank sum tests.
Logistic regression models were used to examine
he effect of the presence or absence of DM and
KD on the prevalence of abnormal and high-risk
can after adjustment for age, history of myocardial
nfarction (MI), hypertension, hyperlipidemia, and
VEF.
Diabetic (n  640)
Value
eGFR>60 ml/min
(n  356)
eGFR<60 ml/min
(n  284) p Value
.0001 63 8 69 9 0.0001
.07 99% (351) 96% (273) 0.08
.3 32% (114) 32% (137) 0.84
.01 28% (99) 24% (67) 0.27
.04 81% (287) 84% (238) 0.12
.13 41% (146) 43% (121) 0.74
.48 19% (68) 20% (56) 0.92
.02 81% (289) 78% (221) 0.34
.001 31% (109) 27% (76) 0.32
.74 11% (41) 12% (33) 0.93
.0001 76 12 42 14 0.001
.55 64% (229) 61% (175) 0.57
.0001 65% (231) 84% (239) 0.0001
.19 63% (209) 71% (196) 0.04
.24 72% (237) 69% (189) 0.5
.0001 20% (62) 29% (79) 0.005
.15 70% (230) 71% (196) 0.68
.001 54 12 50 14 0.02
.0001 18% (64) 24% (68) 0.05
artery disease; CCB  calcium channel blocker; eGFR  estimated glomerularp
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
ary
Pharm  pharmacological; SOB  shortness of breath.
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738The Cox proportional hazards models that ex-
mined presence or absence of DM and CKD in
elation to CD were adjusted for potential con-
ounders, including age, hypertension, hyperlipid-
mia, ejection fraction (EF) 40%, pharmacologi-
al stress test, history of MI, SSS 4, as well as
ardiovascular characteristics/symptoms including
ngina, shortness of breath, and EF. Selection of
ariables for consideration for entry into the model
as based on both clinical judgment (established
rognostic variables) and whether findings from
nivariable analyses reached a significance level of
 0.15. As such, sex and smoking were not
ncluded in the model. The first-order interaction
etween presence or absence of DM and CKD and
SS (SSS categories), SDS (presence of ischemia),
r SRS (presence of scar) was tested by including
0%
SSS<4 SSS 4-8 SSS>8
10%
20%
30%
50%
40%
60%
70%
65%
55%
49%
23%24%
18% 17%
21%
28%
31
No DM, No CKD DM only
Figure 1. Stress Myocardial Perfusion Proﬁles on the Basis of D
The presence and severity of perfusion abnormalities was more pre
disease (CKD) only (p  0.0001), and DMCKD groups (p  0.0001
only, CKD only, and DMCKD had a lower percentage of normal sc
those without DM and CKD (p  0.03 for DM only, p  0.0001 for
score; SRS  summed rest score; SSS  summed stress score.
Table 2. Adjusted OR (95% CI) for Abnormal MPI and High-Risk
Abnormal MPI High-Risk
OR (95% CI) p Value OR (95% CI)
No DM No CKD Referent Referent
DM only 1.48 (1.41–1.93) 0.02 1.67 (1.10–2.56)
CKD only 2.00 (1.51–2.65) 0.001 2.04 (1.32–3.15)
DMCKD 2.43 (1.79–3.29) 0.0001 2.67 (1.73–4.12)
Abnormal myocardial perfusion imaging (MPI) (summed stress score [SSS] 4);
logistic regression models controlling for age, history of myocardial infarction,
CI  conﬁdence interval; CKD  chronic kidney disease; DM  diabetes mellitus.ach of them in the separate Cox proportional
azards model that also included the presence or
bsence of DM and CKD and the nuclear perfusion
ariable of choice. The proportionality assumption
f the Cox model was assessed by including time-
ependent interactions of each covariate with sur-
ival time in the model. There was no evidence of
iolation of this assumption for any covariate. Sim-
lar to the Hosmer-Lemeshow test for logistic
egression, the goodness of fit test for the Cox
roportional hazards model was performed (22). All
tatistical analyses were performed with SAS ver-
ion 9.1.2 (SAS Institute, Cary, North Carolina).
tatistical significance was defined as 2-tailed p 
.05 for all tests.
The authors had full access to the data and take
esponsibility for the integrity of the data. All
 2-6 SDS>6 SRS 2-6 SRS>6
7%
9% 10%
15%
20%
23% 22%
13%
19%
21%
3% 44%
CKD only DM + CKD
KD Status
nt in the diabetes mellitus (DM) only (p  0.004), chronic kidney
mpared with No DM No CKD groups. Similarly, patients with DM
and a higher prevalence of scar and ischemia compared with
only and DMCKD, respectively). SDS  summed difference
n
n SSS >8 EF <40%
Value OR (95% CI) p Value OR (95% CI) p Value
Referent Referent
0.01 1.3 (0.92–1.7) 0.12 1.9 (1.3–2.7) 0.0001
0.001 1.7 (1.2–2.3) 0.001 2.04 (1.4–2.9) 0.0001
0.0001 1.76 (1.2–2.4) 0.001 3.03 (2–4.4) 0.0001
-risk scan (SSS 8 and/or ejection fraction [EF] 40%). Odds ratios (ORs) from
rtension, hyperlipidemia, and EF.SDS
%
37%
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739uthors have read and agree to the manuscript as
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E S U L T S
aseline characteristics. Baseline characteristics of
he 1,747 patients included in the analyses stratified
y DM/CKD status are summarized in Table 1.
atients with CKD in both diabetic and nondia-
etic groups were older, more likely to undergo
harmacological stress, and tended to take calcium
hannel blockers more frequently. They also had a
ower mean EF and a higher prevalence of left
entricular systolic dysfunction (EF 40%) com-
ared with those without CKD. Patients with
KD were more likely to be hypertensive and had
ower prevalence of smoking, hyperlipidemia, and
ngina. Overall, diabetic patients were significantly
ore overweight and obese compared with nondi-
betic persons. Diabetic patients with CKD were
ore likely to use beta blockers. By contrast, there
as no difference in terms of history of CAD, MI,
evascularization, or use of other drugs including
ngiotensin-converting enzyme inhibitors, angio-
ensin receptor blockers, statins, and nitrates.
yocardial perfusion defects and left ventricular dys-
unction on the basis of DM and CKD status. Figure 1
hows the distribution of perfusion abnormalities
n the basis of DM and CKD status. The presence
nd severity of perfusion abnormalities was more
revalent in the DM only (p  0.004), CKD only
p 0.0001), and DMCKD groups (p 0.0001)
ompared with the no DM no CKD group. Simi-
arly, patients with DM only, CKD only, and
MCKD had a lower percentage of normal scans
nd a higher prevalence of scar and ischemia com-
ared with those without DM and CKD (p  0.03
or DM only, p  0.0001 for CKD only and
MCKD, respectively).
On the basis of logistic regression model control-
ing for age, history of MI, hypertension, hyperlip-
demia, and EF, patients with DM only, CKD
nly, or DMCKD had statistically significant
igher odds of having an abnormal scan or a
igh-risk scan compared with those with no DM
o CKD (Table 2).
vent rate on the basis of DM and CKD status. During
mean follow-up period of 2.15  0.8 years, total
vents included 225 deaths from all causes, 119
Ds, and 185 composite (CD/NFMI) events. Pa-
ients with CKD only and DMCKD had a 2- and
-fold higher CD and all-mortality rate, respec-
ively, compared with those in no DM No CKDnd DM only groups (all log-rank p  0.0001).
here was no statistical difference in the event rate
f CD, ACM, and CD/NFMI between patients
ith DM only and no DM no CKD groups. Even
fter excluding patients who underwent early revas-
ularization (60 days), a similar trend persisted for
utcomes.
Patients who experienced any of the outcomes
CD, ACM, and CD/NFMI) during the course of
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Figure 2. Kaplan Meier Survival Analysis for Freedom From Car
Log-rank p value 0.0001 for comparisons between No DM No CKD
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740he study had statistically significant lower renal
unction (demonstrated by median eGFR) or
reater number of perfusion defects (demonstrated
y SSS and SDS values). The median SSS and SDS
ere higher in patients with CD compared with
hose without this end point (SSS 9.0 vs. 2.0, p 
.0001; SDS 3.0 vs. 1.0, p 0.0001). Patients with
D also had a lower median eGFR compared with
Time (Days)
0 500 750 1000 1250 1500
7 259 150 65 10 0
3 276 170 88 19 1
7 217 119 65 16 0
5 601 357 151 45 1
M, No CKD
 alone
tatus:
 CKD
lone
r Survival Analysis for Freedom From CD/NFMI
001 for comparisons between No DM No CKD and DM alone ver-
CKD. The log-rank p test for No DM No CKD and DM only
cant (log-rank p  0.33). CD  cardiac death; NFMI  nonfatal
other abbreviations as in Figure 1.
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Rate on the Basis of MPI and DM/CKD Status
increase in CD rate with increasing severity of perfusion defects
n the basis of DM and CKD status (all log-rank p  0.001). The
sed with increasing severity of SSS. MPA  myocardial perfusion1
reviations as in Figures 1 and 4.hose without CD (51.6 vs. 67.3, p  0.0001).
aplan Meier survival plot showing survival free
rom CD is shown in Figure 2. The survival
robabilities for patients with CKD only and
MCKD were significantly lower than for those
ith DM only and the no DM no CKD group (all
og-rank p  0.01). The log-rank p test for no DM
o CKD and DM only groups was not significant
log-rank p  0.73). Patients with both CKD and
M had a decrement in survival that was greater
han the combined individual effects of DM and
KD, respectively, suggesting a negative synergistic
ffect of these 2 variables on survival (p  0.0001).
imilar trends were noted for ACM (Fig. 3) and
D/NFMI (Fig. 4).
erfusion defects and outcomes. There was a signif-
cant increase in CD rate with increasing severity of
erfusion defects across all subgroups on the basis of
M and CKD status (all log-rank p  0.001)
Fig. 5). Patients in the mildly abnormal (SSS 4 to
) and moderate to severely abnormal MPI (SSS
8) groups had statistically significant higher inci-
ence of CD compared with normal MPI. This
ffect was further magnified among subgroups of
KD alone and DMCKD compared with the
M alone and no DM no CKD groups. Regarding
D in particular, a normal myocardial perfusion
tudy in patients without CKD (with or without
M) was associated with a low CD rate (0.9%/
ear). Conversely, the CD rate was 3 times higher
or patients with normal scans but with CKD only
2.35%/year) and DMCKD (2.9%/year) (Fig. 5).
here was no significant interaction between dis-
ase status and SSS categories (p  0.35).
Presence of ischemia and scar as determined by
he severity of SDS and SRS was associated with
igher risk of CD. The event rate increased with
ncreasing severity of ischemia and scar across all
ubgroups on the basis of DM and CKD status.
his effect appeared more pronounced in patients
ith CKD and DM and CKD (Figs. 6A and 6B).
here was no significant interaction between dis-
ase status and ischemia (SDS) categories (p 
.73). Similarly, there was no significant interaction
etween disease status and scar (SRS) categories
p  0.73).
redictors of cardiac outcomes by multivariable analy-
is. The results from the Cox proportional hazards
odel for the end point of CD are shown in
able 3. The presence of DM and CKD was a
ignificant predictor of increased CD with a hazard
atio (HR) of 2.70 (95% confidence interval [CI]:Su
rv
iv
al
 P
ro
ba
bi
lit
y 
(%
)
50
60
70
80
90
100
0 25
Number at Risk
Group: CKD alone
 348 31
Group: DM alone
 356 33
Group: DM + CKD
 283 25
Group: No DM, No CKD
 759 71
No D
CKD
DM, CKD S
DM +
DM a
Figure 4. Kaplan Meie
Log-rank p value 0.0
sus CKD alone and DM
groups was not signiﬁ0%
No DM, No C
Ev
en
ts
/Y
ea
r
2%
4%
6%
16%
10%
12%
18%
8%
14%
0.9%
3.7% 3
Figure 5. Annual CD
There was a signiﬁcant
across all subgroups o
incidence of CD increa.59 to 4.58, p  0.0001). Other significant mul-
t
1
0
9
C
a
C
(
s
n
e
s
3
t
H
s
s
c
(
E
f
s
C
t
w
c
l
C
t
D
O
o
f
E
o
h
c
fi
d
m
c
p
f
g
n
i
t
d
c
e
r
s
d
a
w
a
s
f
n
b
o
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 3 , N O . 7 , 2 0 1 0
J U L Y 2 0 1 0 : 7 3 4 – 4 5
Hakeem et al.
Renal Function, SPECT, and Outcomes in Diabetic Patients
741ivariable predictors of CD were age 65 (HR:
.84, 95% CI: 1.21 to 2.80), hyperlipidemia (HR:
.40, 95% CI: 0.27 to 0.59), EF 40% (HR: 4.05;
5% CI: 2.58 to 6.36), and SSS4 (HR: 2.28, 95%
I: 1. 36 to 2.83). There was no significant inter-
ction between the presence or absence of DM and
KD and all other covariates. The model fits well
p value for goodness-of-fit  0.14; the Harrell’s C
tatistic  0.84).
An additional multivariable analysis model (result
ot shown) comprising patients with high-risk (mod-
rate to severely abnormal MPI and EF 40%)
howed that patients with DMCKD had an HR of
.17 (95% CI: 1.75 to 5.74) for CD compared with
hose high-risk patients without DM and CKD.
istory of CAD and outcomes on the basis of DM/CKD
tatus. Patients with a history of CAD had a
ignificantly lower survival free of CD/NFMI as
ompared with those without history of CAD
6.7%/year vs. 3.6%/year; log-rank p  0.0001).
vent rates on the basis of CAD history with
urther stratification on the basis of DM/CKD
tatus for the end points of CD, ACM, and
D/NFMI are shown in Table 4. Overall, the
rends were similar to the entire cohort. Patients
ith DM/CKD had a 3- to 4-fold higher CD rate
ompared with those without DM or CKD, regard-
ess of history of CAD. In either group, those with
KD had worse outcomes, regardless of DM sta-
us, compared with those without CKD (Fig. 7).
I S C U S S I O N
ur study examined the impact of CKD and MPI
n risk stratifying diabetic and nondiabetic patients
or adverse cardiac events. After controlling for age,
F, CAD, hypertension, dyslipidemia, and previ-
us MI, we found that diabetic persons with CKD
ad significantly higher predicted rates of CD
ompared with counterparts without CKD. This
nding was in keeping with previous studies that
emonstrated an increased risk of cardiovascular
ortality and ACM in patients with renal insuffi-
iency (23,24). However, we also found that the
resence of CKD alone without DM was a power-
ul determinant of cardiac mortality, perhaps stron-
er than the presence of diabetes alone, because
ondiabetic patients with CKD had a several-fold
ncreased risk of CD compared with diabetic pa-
ients without CKD. The absence of CKD in
iabetic patients might portend a lower risk, be-
ause diabetic patients without CKD had a low pvent rate in a relatively short term, almost compa-
able to patients without diabetes or CKD.
We also found that MPI provides effective risk
tratification for cardiac events on the basis of
iabetes and CKD status. Although the presence of
normal scan confers a lower risk in CKD patients
ith and without diabetes, the presence of CKD
dversely effects the warranty period of a normal
can. Diabetic patients with CKD have a several-
old higher risk of death even in the presence of a
ormal scan, as do nondiabetic patients with CKD,
ut the risk is relatively lower. Lastly, the presence
f DM and CKD strongly correlates with the
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742strong correlation with the presence of a high-risk
can.
The associations among cardiovascular disease,
KD, and increased cardiac mortality have been
eported previously in the general population (25–
7), in patients with known CAD undergoing PCI
28,29) and asymptomatic diabetic persons under-
oing stress myocardial perfusion imaging (30), but
ur results also highlight the important point that
iabetic persons are a heterogeneous group and that
he absence of CKD in diabetic patients might
ortend a relatively benign short-term risk.
KD as a cardiovascular risk factor. The connections
etween CKD and CVD are numerous. CKD is
ssociated with many traditional risk factors for
ardiovascular disease, including smoking, hyper-
ension, dyslipidemia, physical inactivity, diabetes,
nd the metabolic syndrome (27,31–34). However,
here are also several nontraditional risk factors for
ardiovascular disease, including increased risk for
eft ventricular hypertrophy from volume and pres-
ure overload, anemia causing increased cardiac
utput, altered bone mineral metabolism leading to
yperphosphatemia and increased vascular calcifi-
ation, increased oxidative stress, and endothelial
ysfunction. Because vascular disease is a systemic
rocess affecting the rich renal vasculature, renal
ysfunction measured by eGFR might serve as a
onvenient, quantifiable measure for atherosclerotic
urden, a value aggregating the various disparate
isk factors.
mplications in risk stratifying diabetic persons. With
uch a high burden for cardiovascular mortality in
Table 3. Multivariable Analysis for CD Cox Proportional
Hazards Model
Variable HR 95% CI p Value
DM/CKD category
No DM No CKD Referent
DM only 1.03 0.54–1.97 0.93
CKD only 1.58 0.92–2.71 0.09
DMCKD 2.70 1.59–4.58 0.0001
Age 65 1.84 1.21–2.80 0.004
SOB 1.54 0.92–2.59 0.10
Angina 0.91 0.57–1.44 0.68
Hypertension 0.76 0.49–1.17 0.21
Hyperlipidemia 0.40 0.27–0.59 0.0001
History of MI 0.96 0.62–1.49 0.87
EF 40% 4.05 2.58–6.36 0.0001
Pharm stress test 1.72 0.98–3.00 0.06
SSS 4 2.28 1.36–3.83 0.002
CD cardiac death; HR hazard ratio; other abbreviations as in Tables 1 and 2.iabetic persons, noninvasive imaging has beenroposed to risk stratify diabetic persons and iden-
ify those patients with a higher burden of athero-
clerotic disease before a cardiac event. Although
here are limited prospective data, there are a
umber of retrospective studies showing a benefit to
oninvasive stress testing to risk stratify diabetic
atients (35,36). Given the vast number of diabetic
ersons and the enormous cost for asymptomatic
creening, there have been several attempts to
dentify high-risk diabetic persons who would most
enefit from such an aggressive screening strategy.
Unfortunately, the use of 2 or more traditional
ardiovascular risk factors has not predicted induc-
ble ischemia on nuclear or echocardiographic myo-
ardial perfusion imaging (37–39). Coronary artery
alcium scores have also been proposed to identify
atients with high likelihood of inducible ischemia
n imaging (40,41) and have been prospectively
tudied in asymptomatic diabetic persons (39). Re-
ults of the DIAD trial showed that screening for
ilent ischemia with myocardial perfusion imaging
esting in diabetic patients was not associated with
reduction in cardiovascular events (12). The
IAD cohort, however, had a very low cardiac
vent rate (average, 0.6%/year) translating into a
4% power to detect the originally anticipated
ifference between the groups. Although the low
vent rate precluded any multivariable analysis, age-
nd sex-adjusted analysis revealed microalbumin-
ria/proteinuria and serum creatinine to be predic-
Table 4. Annualized Event Rate on the Basis of History of CAD
and DM/CKD Status
No History of CAD
(n  1,015)
History of CAD
(n  732)
p
Value
No DM No CKD
CD 1.53% 1.9% 0.64
ACM 5% 3.8% 0.26
CD/NFMI 2.2% 4% 0.04
DM only
CD 1.3% 2.8% 0.2
ACM 4% 5.4% 0.43
CD/NFMI 3.7% 5.4% 0.34
CKD only
CD 4.4% 4.7% 0.9
ACM 8.8% 8.4% 0.9
CD/NFMI 5.1% 8.2% 0.1
DMCKD
CD 5.1% 9.2% 0.05
ACM 7.4% 9.6% 0.41
CD/NFMI 5.7% 12.6% 0.002
ACM  all-cause mortality; NFMI  nonfatal myocardial infarction; other abbre-
viations as in Tables 1 and 2.
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743ors of the primary outcomes. One major limitation
f the DIAD study was stratification of the popu-
ation on the basis of serum creatinine. Crude
reatinine measurement is known to underestimate
enal function (20,21).
Our study suggests that eGFR has a paramount
ole in identifying high-risk diabetic persons at
ighest risk for abnormal nuclear scans and CD.
urthermore, given the ubiquity of creatinine mea-
urements in standard metabolic panels and the
elative ease of calculating eGFR via the MDRD
quation, this risk stratification tool would not
equire an additional test with the added cost and
adiation risks.
Additionally, perfusion defects on MPI imaging
rovide substantial prognostic information in pre-
icting adverse outcomes in both diabetic and
ondiabetic patients. Together, both perfusion de-
ects and eGFR are powerful risk predictors and
rovide additive and effective risk stratification in
iabetic persons.
tudy limitations. This study was a retrospective
nalysis with the inherent limitations of this design.
oreover, the study was conducted on a population
f predominantly white male veterans with a base-
ine high prevalence of CKD and CAD risk factors.
ther racial subsets were under-represented, pre-
luding race-based analysis. For diabetic patients,
ata on medication regimen, hemoglobin A1C
evels, proteinuria, and retinopathy were all unavail-
ble, preventing the determination of whether level
f glycemic control had any interaction with cardiac
ortality. This study was conducted in a single
enter and followed patients for a mean of 2 years,
reventing determination of long-term clinical out-
omes. Perfusion defects were semiquantitatively
ssessed with a 20-segment model, which has the
imitation of over-presenting the apex when com-
ared with anatomic data compared with a 17-
egment model. We used a 4-min adenosine infu-
ion as compared with the standard 6-min
denosine infusion. The standard protocol includes
min of adenosine infusion; concern remains about
uboptimal vasodilatation with a shorter duration of
denosine infusion. Although there are no random-
zed trials comparing 4-min versus 6-min adenosine
nfusion, a consensus statement from the American
ociety of Nuclear Cardiology agrees that “a
horter-duration adenosine infusion, lasting 4 min,
as been found to be equally effective for the
etection of CAD compared with the 6-min infu-
ion” (42). Additionally, there could have been rossible selection bias of sending patients with DM
nd CKD or CKD alone to stress imaging.
O N C L U S I O N S
hronic kidney disease defined by eGFR 60
l/min/1.73 m2 and myocardial perfusion defects
re powerful prognostic indicators to help identify
iabetic persons at high risk for both cardiac and
CM. Diabetic patients without CKD have a
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744able to nondiabetic patients. Hence the increased
ardiovascular morbidity in diabetic persons might
argely be due to underlying renal dysfunction.
hus, the use of eGFR might play an important
ole in identifying high-risk diabetic persons who
ould benefit most from myocardial perfusion im-
ging. Presence of a normal scan in diabetic persons
ith CKD or those with CKD alone is associatedafter myocardial infarction. N Engl J
Med 2004;351:1285–95.
technetium-99m se
perfusion single-tudies are warranted to evaluate the impact of
ifferent cardiovascular prevention and manage-
ent strategies in diabetic persons with CKD.
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